E319
CAS 1948-33-0
E319 (CAS 1948-33-0) is a pharmaceutical compound with 5 bioactivity targets and 0 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | Potency | 31903.768292682926 nM | 72 | - |
| - | GI50 | 58225.806333333334 nM | 60 | - |
| - | EC50 | 32214 nM | 10 | - |
| - | IC50 | 51912.5 nM | 8 | - |
| - | IC50 | 14.46 ug.mL-1 | 1 | - |
Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| TBHQ | 1362739 | SU | MTHSPL |
| TERT-BUTYLHYDROQUINONE | 1362739 | SU | MTHSPL |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is E319 used for in pharmaceutical contexts?
E319 (CAS 1948-33-0) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for E319?
No adverse-event association or SIDER side-effect rows are rendered for E319 in this page query. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is E319 also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for TBHQ (tert-Butylhydroquinone) with EU status "permitted".
What clinical phase is E319 in?
No phase 1-4 clinical development badge is rendered for E319 because the matched compound identifier rows do not contain a max-phase value.